ical Study Group for their excellent assistancein the conduct, reporting, and quality controlof the study and all of the patients who volun-teered to participate. In addition, the followingindividuals are gratefully acknowledged fortheir valuable contributions to the conduct,reporting, and quality control of the study andto the development of the manuscript: MiriamAhern, Roberta Allen, Maria Aisporna,Thomas Bicsak, Amy Halseth, John Hol-combe, Orville Kolterman, Szecho Lin, DavidMaggs, Loretta Nielsen, Terri Poon, LarryShen, Michael Sierzega, Kristin Taylor, Mi-chael Trautmann, Amanda Varns, BarbaraWilkinson, Matthew Wintle, and Liping Xie. References 1. DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131:281–303, 1999 2. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 137:25–33, 2002 3. Nathan DM: Initial management of glyce- mia in type 2 diabetes mellitus. N Engl J Med 347:1342–1349, 2002